HK1257583A1 - Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine - Google Patents

Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine

Info

Publication number
HK1257583A1
HK1257583A1 HK18116702.5A HK18116702A HK1257583A1 HK 1257583 A1 HK1257583 A1 HK 1257583A1 HK 18116702 A HK18116702 A HK 18116702A HK 1257583 A1 HK1257583 A1 HK 1257583A1
Authority
HK
Hong Kong
Prior art keywords
medicine
preventing
related diseases
fat metabolism
metabolism disorders
Prior art date
Application number
HK18116702.5A
Other languages
Chinese (zh)
Inventor
李季男
Original Assignee
深圳瑞健生命科學研究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳瑞健生命科學研究院有限公司 filed Critical 深圳瑞健生命科學研究院有限公司
Publication of HK1257583A1 publication Critical patent/HK1257583A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18116702.5A 2016-12-15 2018-12-28 Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine HK1257583A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611162237 2016-12-15
CN201611161347 2016-12-15

Publications (1)

Publication Number Publication Date
HK1257583A1 true HK1257583A1 (en) 2019-10-25

Family

ID=62656680

Family Applications (7)

Application Number Title Priority Date Filing Date
HK18116275.2A HK1257239A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating obesity and use of the medicine
HK18116272.5A HK1257236A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating hyperlipemia diseases and use of the medicine
HK18116273.4A HK1257237A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating fatty liver and use of medicine
HK18116270.7A HK1257234A1 (en) 2016-12-15 2018-12-19 Medicine for treating coronary atherosclerosis as well as complications of coronary atherosclerosis and use of the medicine
HK18116276.1A HK1257240A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine
HK18116269.0A HK1257233A1 (en) 2016-12-15 2018-12-19 Medicine for preventing atherosclerosis and complications of atherosclerosis and use of medicine
HK18116702.5A HK1257583A1 (en) 2016-12-15 2018-12-28 Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine

Family Applications Before (6)

Application Number Title Priority Date Filing Date
HK18116275.2A HK1257239A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating obesity and use of the medicine
HK18116272.5A HK1257236A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating hyperlipemia diseases and use of the medicine
HK18116273.4A HK1257237A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating fatty liver and use of medicine
HK18116270.7A HK1257234A1 (en) 2016-12-15 2018-12-19 Medicine for treating coronary atherosclerosis as well as complications of coronary atherosclerosis and use of the medicine
HK18116276.1A HK1257240A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine
HK18116269.0A HK1257233A1 (en) 2016-12-15 2018-12-19 Medicine for preventing atherosclerosis and complications of atherosclerosis and use of medicine

Country Status (2)

Country Link
CN (8) CN108210902A (en)
HK (7) HK1257239A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108671226A (en) * 2018-08-08 2018-10-19 广州铭康生物工程有限公司 The drug and application thereof of effective therapeutic community ductus venosus complication
CN110093412A (en) * 2019-03-29 2019-08-06 南方医科大学南方医院 For the molecular marker UGP2 of diagnosing atherosclerotic and application
CN111100928A (en) * 2020-01-09 2020-05-05 武汉科技大学 Atherosclerosis biomarker and atherosclerosis diagnosis kit
CA3169325A1 (en) * 2020-02-26 2021-09-02 Jinan Li Method and drug for preventing and treating abnormal blood pressure condition
CN112305120B (en) * 2020-10-30 2022-02-08 河北医科大学第二医院 Application of metabolite in atherosclerotic cerebral infarction

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408431A (en) * 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 Gene engineering medicine for curing diseases relative to vascularization
MXPA04007585A (en) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms.
JP2006507297A (en) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス Treatment and prevention of abnormal scar formation in keloids and other skin or internal wounds or lesions
CN101518535A (en) * 2002-12-06 2009-09-02 法布罗根股份有限公司 Fat regulation
MXPA05006287A (en) * 2002-12-10 2005-09-08 Wyeth Corp Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1).
JPWO2005026127A1 (en) * 2003-09-11 2006-11-16 株式会社医薬分子設計研究所 Plasminogen activator inhibitor-1 inhibitor
PL2246417T3 (en) * 2004-04-22 2015-06-30 Grifols Therapeutics Inc Recombinantly modified plasmin
WO2006095713A1 (en) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. Inhibitor of plasminogen activator inhibitor-1
JPWO2007111242A1 (en) * 2006-03-24 2009-08-13 ロート製薬株式会社 Metabolic syndrome improving agent
CN101573134B (en) * 2006-08-28 2013-03-06 李季男 Candidates against infection
WO2008051794A2 (en) * 2006-10-20 2008-05-02 Dow Global Technologies Inc. Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
US20090239868A1 (en) * 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
CN102872020A (en) * 2007-10-23 2013-01-16 株式会社医药分子设计研究所 Inhibitor of pai-1 production
CN102482338B (en) * 2009-07-10 2016-09-28 斯路姆基因公司 Plasminogen and the variant of fibrinolysin
HUE029550T2 (en) * 2009-08-12 2017-03-28 Univ Cornell Methods for preventing or treating metabolic syndrome
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN103384722B (en) * 2011-01-05 2016-11-16 斯路姆基因公司 Plasminogen and fibrinolysin variant
WO2012119078A2 (en) * 2011-03-03 2012-09-07 Tersus Pharmaceuticals, LLC COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE
CN102188699A (en) * 2011-05-06 2011-09-21 南京农业大学 Pharmaceutical composition for treating atherosclerosis, and preparation method and application thereof
KR20140064841A (en) * 2011-08-12 2014-05-28 쓰롬보제닉스 엔.브이. Plasminogen and plasmin variants
CN102532326B (en) * 2011-11-18 2017-06-09 南京大学 A kind of human fiber plasminogen Kringle 5 variant of cancer target and its application
JP6696899B2 (en) * 2013-08-13 2020-05-20 サノフイＳａｎｏｆｉ Antibody against plasminogen activator inhibitor-1 (PAI-1) and use thereof
WO2015026494A2 (en) * 2013-08-20 2015-02-26 Trustees Of Dartmouth College Methods for treating tissue fibrosis

Also Published As

Publication number Publication date
CN108210898A (en) 2018-06-29
CN108210902A (en) 2018-06-29
CN108210904A (en) 2018-06-29
CN108210896A (en) 2018-06-29
CN108210906A (en) 2018-06-29
CN108210895A (en) 2018-06-29
HK1257233A1 (en) 2019-10-18
HK1257236A1 (en) 2019-10-18
HK1257240A1 (en) 2019-10-18
HK1257237A1 (en) 2019-10-18
CN108210900A (en) 2018-06-29
HK1257234A1 (en) 2019-10-18
HK1257239A1 (en) 2019-10-18
CN108210914A (en) 2018-06-29

Similar Documents

Publication Publication Date Title
IL298689B1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
HK1246712A1 (en) Nerve stimulation for treatment of diseases and disorders
IL262608A (en) Combination treatment of ocular inflammatory disorders and diseases
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
PT3377637T (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
IL267210A (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
IL271117B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
HK1257583A1 (en) Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine
IL273550A (en) Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
PL3405215T3 (en) Methods for the treatment of danon disease and other disorders of autophagy
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
HK1257585A1 (en) Medicine for preventing and treating skin fibrosis and use of the medicine
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
IL272097A (en) Compounds for the prevention and treatment of medical disorders and uses thereof
IL269400A (en) Drugs and compositions for the treatment of ocular disorders
HK1257238A1 (en) Medicine for preventing and treating lipid kidney injury and use of the medicine
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
PL3515409T3 (en) Complex and compositions for the treatment of ophthalmic and dermatological diseases
IL274132A (en) Treatment of skin disorders
AU2016904007A0 (en) Implants for the Treatment of Diseases and Disorders
GB201622465D0 (en) Treatment of muscular and skeletal disorders in animals